Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum

Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum. The presentation will take place on Friday, June 3, 2016 at 12:40 p.m. CT at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL. 

The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.

About Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301.  NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302.   For more information, visit www.galenabiopharma.com.

NeuVax is a trademark of Galena Biopharma, Inc.

 

Contact:

Remy Bernarda
SVP, Investor Relations & Corporate Communications
[phone]
[e-mail]